Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium

Stefano Ferrari(University of Padua), Rachel Steel(Imperial College London), Maurizio Scarpa(University of Udine), William H Colledge(University of Cambridge), DM Geddes(Imperial College London), Chris Marriott(King's College London), DA Parkins(GlaxoSmithKline (United Kingdom)), R Farley(Imperial College London), MJ Evans(Cardiff University), Brandon J. Wainwright(The University of Queensland), Chris Kitson(GlaxoSmithKline (United Kingdom))
Gene Therapy
September 1, 2001
10.1038/sj.gt.3301525
Cited by 119

Related Papers

The <i>GPR54</i> Gene as a Regulator of Puberty
|New England Journal of Medicine|2003|2.5k
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation
|Blood|2010|517
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307